

Using a ML-Enabled EMR Provider Workflow to Improve Patient Care & Streamline Non-Clinical Tasks

SHPCP October 2023 Lunch & Learn





No Time For Healthcare ?





Omar Mohtar (MD/PHD)

Founder **Chief Executive Officer**



Boston University School of Medicine



Spent half of workday doing paperwork

Not enough time with patients. I'm not alone

Doctors unable to practice at the top of their license

Texas Medical Center Innovation Surveyed 100 doctors in Houston...

BIODESIGN









outpatient visit

PATIENTS million Medicare* patients in 2023





Why Now?

increase^{**} since 2010

Spent on Reporting!!

*** Bain & Company (2023 Report)







Health Plans capture proof-of-work from providers for approvals, reimbursement, and financial incentives





We can optimize quality care and reporting without burdening healthcare providers?



Mid-sized Clinic 3,000 patients / month

Problem:

- 5x documentation volume
- Manually Intensive Process
- Care gaps fall between cracks

Impact:

- 5 week study
- 10 minutes saved / visit
- **Additional Revenue Stream for Practice**
- Decrease overhead
- New patient visits

More patient engagement



- Increase reimbursement





Dr. Glenn Davis, MD

Working with ParaDocs Health allowed me to spend more time with patients and accurately fill out the necessary paperwork for reimbursement.



Augmented-Automation Workflow



Retrieve Reporting form & provider notes from patient visit

Determine optimal care codes from Data Lake





Automate form with supporting clinical evidence

SUBMIT One-click approval & submission

Confidential © 2023 ParaDocsHealth





Patient Assessment Form Study

	te Optum in-office assessment program (29 date(s) of service; past screening of). Use for		74	. 6	-1
aonum	pation is eligible for up to \$XX when sub toly and timely. Administrative Reimbursement.	9	ubmit via traceable carri scure fax (1-972-957-21 ee > Additional Instruc	45).	Ser, or	뷣	õ	÷	2
► P	atient: MbrLastName, Mbrl	FirstName				_ <u></u>	- 3	Fr.	
м	ember ID: XXXXXXXX D	OB: MM/DD/Y	YYY Phor	no: ###-###-#			le:		5
ÞP	rovider Information	Check box	to confirm the provider of	completing the ass	sessment. Er	ter name P	4P1 if not	peoule	sed.
C	Provider: PCP Name 1				NP1:			_	
	Provider:				NPI:				
> C	are Priority: 1 ① Emergen	cy Room visits (3),	High Risk Medications	(3), Medication	Adherence	Gap (3)			
conditi sunpe	ngoing Assessment & Eval on was evaluated, present and appropr ted condition is reported as 'Assessed ions assessed during the encounter. Potential Diagnosis Designate Specificity	istely documented o		must be support over Name and De	ed in the med ale of Service Assessed and	fical chart p must be n Assessed and Not	provided.	E any overin	g al ot
135	Acute Renal Failure (N17)		GFR test value was t	57.9	Diagnosed	Diagnosed	Referred	Asse	7
322	Morbid Obesity (E66.01, E66.2, Z68	4-1	Previously Coded: M	orbid Obesity	-		α	ľ.	1
157	Pressure Ulcer w/ Necrosis to Must consider location, laterality & stage		Previously Coded (C) Necrosis (733,XX)	D-10: Asoptic	0	D	-	1	3
soveri Evalue	suspected condition is reported above a ng all conditions assessed during the en sting Practitioner Name.	counter.	Date of S	ervice:					
Evalua Evalua P	ng all conditions assessed during the er sting Practitioner Name. reventive Medicine Screeni flowing screening(s) are due or eventue	ng	Date of S Indicate if screenin	ervice: ng/referral(s) were	completed b	ly checking	the app	opriate	a bo
Evalua D P The fo	ng all conditions assessed during the en sting Practitioner Name. reventive Medicine Screeni	ng	Date of S Indicate if screenin	ervice: ng/referral(s) were	completed b	ly checking ia, and exc	the app	opriate	a be
Evalue Evalue The to notice Boree Body	ng all conditions assessed during the en sting Practitioner Name. reventive Medicine Screeni flowing acreening(s) are due or eventue led in medical record documentation	ng	Date of S Indicate if screenin DBS & health plan data s assessment. Outcome	ervice: ngirefernal(s) were Evidence of res	completed b	ly checking Is, and exc Excl	the appr stusions usion	opriate	a be
Soveri Evaluation D P The to includ Bone Bone Bone Bone Bone Bone Bone Bone	ng all conditions assessed during the en ting Practitioner Name	counter: ng as indicated by Hill submitted with thi Gompleter	Date of S Indicate if screenin DBS & health plan data s assessment. Outcome d	ervice: ngirefernal(s) were Evidence of res	i completed t wita, referra	ex D Pre	the appr stusions usion	opriato must	be
Soveri Evalue D P The fo inclue Bone Bone Bone Bone Bone Bone Bone Bon	ng all conditions assessed during the en ating Practitioner Name. reventive Medicine Screeni flowing screening(s) are due or eventual led in medical record documentation mings to Consider Mass Index (BMI & Weight required) tecommended for adults 18-74 at each levit visit t Cancer Screening to claims for breast cancer screening in 1	counter: ng as indicated by Hill submitted with thi Completer the Completer	Date of S Indicate if screenin DBS & health plan data sassessment. Outcome d	ervice: rg/referral(s) were Evidence of res igh	i completed t ults, referra	ex Development ex Development ex Development ex Development ex Development ex Development ex Development master	the appr stusions usion ignant steral Ma inilateral	opriatx must stecto	a bo be
Soveril Evalue D P The fo inclus Bone Body R Breas N Southal Southal S	ng all conditions assessed during the en ating Practitioner Name. reventive Medicine Screeni Itowing acreening(a) are due or eventual led in medical record documentation mings to Consider Mass Index (BMI & Weight required) acommended for adults 16-74 at each level visit t Cancer Screening to claims for breast cancer screening in the t or prior datendar year actal Cancer Screening to claims for facal occut screening in the t months: sigmoidoscopy in least 5 years	counter: ng as indicated by Hill submitted with thi Completer the Completer	Date of S Indicate if screenin DBS & health plan data sassessment. Outcome d	ervice: ighrefernal(s) were Evidence of res igh	alta, referra	ex Col ex Col ex Col ex Col ex Col ex Col ex Col ex Col ex Col ex Col	the appr stusions usion gnant steral Ma initateral ctomics arectal C al Colec	opriati must stecto lance tomy	a be be
Evaluation	ng all conditions assessed during the en ating Practitioner Name. reventive Medicine Screeni flowing screening(s) are due or overdue led in medical record documentation mings to Consider Mass Index (BMI & Weight required) acommended for adults 18-74 at each levit visit t Cancer Screening to cleme for breast cancer screening in the t or prior datendar year ectal Cancer Screening to clame for facal occut screening in the t months, signoidoscopy in last 5 years lonoscopy in the last 18 years	counter: ng as indicated by Hill submitted with thi Completer indicated by HEDIS	Date of S Indicate if screenin DBS & health plan data sassessment. Outcome d	ervice: rg/referral(s) were Evidence of res igh	a completed t eults, referra Age S Age S Age S	ex Col ex Col ex Col ex Col ex Col ex Col maste ex Col maste ex Col maste	the appr stusion insion ignant deral Ma interal interal correctal C al Colect the appr	opriato must stecto cance tomy opriato	a bo be imy
D P The formet Sorrer Sorrer Sorrer Sorrer Sorrer Sorrer N Sorrer Sorrer N Sorrer Sorrer N Sorrer Sorrer N Sorrer S	In all conditions assessed during the entring Practitioner Name. reventive Medicine Screeni Itowing screening(s) are due or eventual led in medical record documentation mings to Consider Mass Index (BMI & Weight required) ecommended for adults 18-74 at each lecommended for adults 18-74 at e	counter: ng as indicated by Hill submitted with thi Completer for Completer indicated by HEDIS entation submitted Suggeste	Date of S Indicate it screenin Dits A health plan data s assessment. Outcome d □ Unable to wei d □ Referred d □ Referred s & health plan data. Evi s with this assessment ed Action	ervice: rg/referral(s) were Evidence of res igh	a completed t eults, referra Age S Age S Age S	ex Col ex Col ex Col ex Col ex Col ex Col maste ex Col maste ex Col maste	the appr stusion weion grant deral Ma initateral comiete al Colect al Colect al Colect al the appli the appli Yes	opriato must stecto cance tomy opristo cable) N/A	a bo be amy a bo
D P The formet Sorrer Sorrer Sorrer Sorrer Sorrer Sorrer N Sorrer Sorrer N Sorrer Sorrer N Sorrer Sorrer N Sorrer S	In all conditions assessed during the entring Practitioner Name. reventive Medicine Screeni lowing screening(s) are due or eventual led in medical record documentation mings to Consider Mass Index (BMI & Weight required) tecommended for adults 18-74 at each levit visit it Cancer Screening to claims for breast cancer screening in the it or prior dalendar year social Cancer Screening to claims for facal occult screening in the it months: sigmoidoscopy in least 5 years forioscopy in the last 18 years lowing action(s) are due or overtue, as be included in medical record documents in claims and in medical record documents in the included in the interval interval in the interval interval in the interval in the interval interval interval in the interval in	counter: ng as indicated by Hill submitted with thi Completer for Completer Completer indicated by HEDIS entation submitted Suggeste Blood Pre	Date of S Indicate if screenin DBS & health plan data sassessment. Outcome d □ Unable to wei d □ Referred d □ Referred s & health plan dats. Evi t with this assessment ed Action ssure Evaluation	ervice: spirofernal(s) wore Evidence of res igh	a completed t aults, referra Age S Age S Age S Age S a performed t ment or a re	ex Col ex Col ex Col ex Col ex Col ex Col maste ex Col maste ex Col maste	the appr stusion usion grant deral Ma inisteral control al Colect al Colect	opriato must stecto cance tomy opriato cable) N/A	be imy into No
Soveri Evaluation Document Societies Notice Provide Societies Notice Not	In all conditions assessed during the entring Practitioner Name. reventive Medicine Screeni Itowing screening(s) are due or eventual led in medical record documentation mings to Consider Mass Index (BMI & Weight required) ecommended for adults 18-74 at each lecommended for adults 18-74 at e	counter: ng as indicated by Hill submitted with thi Completer ter Completer Completer indicated by HEDIS entation submitted Suggester Blood Pre Diabetic B HbA1c Te	Date of S Indicate if screenin DBS & health plan data sassessment. Outcome d □ Unable to wei d □ Referred d □ Referred s & health plan data. Evi s &	ervice: spirofernal(s) wore Evidence of res igh	a completed t aults, referra Age S Age S Age S Age S a performed t ment or a re	ex Col ex Col ex Col ex Col ex Col ex Col maste ex Col maste ex Col maste	the appr stusion usion grant deral Ma inisteral control al Colect al Colect	opriato must stecto cance tomy opriato cable) N/A	be imy be
Soverill Evaluation Evaluation Production Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Boreas Doublas Boreas Novimer Colore Colore	Ing all conditions assessed during the entiting Practitioner Name	counter: ng as indicated by Hill submitted with thi Completer for Completer Completer Completer Completer Suggests Blood Pre Diabetic E HbA1c Te Nephrope Prescripti	Date of S Indicate if screenin Dits & health plan data s assessment. Outcome d □ Unable to wei d □ Referred d □ Referred s & health plan data. Evi with this assessment ed Action Source Evaluation Eve Exam (Yes indicate esting thy Screening on Treatment	ervice: sg)infernal(s) were Evidence of res igh	a completed t aults, referra Age S Age S Age S Age S a performed t ment or a re	ex Col ex Col ex Col ex Col ex Col ex Col maste ex Col maste ex Col maste	the appr stusion weion grant deral Ma initateral comiete al Colect al Colect al Colect al the appli the appli Yes	opriato must stecto cance tomy opristo cable) N/A	a bo be amy a bo

Key Performance Indicators	2022	2023 🔀			
Number of Forms	160	180			
Personnel Time	30 Hours	5 hours			
Total Submitted	48%	100%			
Time Spent/Month	30 Hrs	5 Hrs			
Accuracy	10%	98%			
Risk-Adjusted Factor (RAF	Risk-Adjusted Factor (RAF) Score Improvement				
Impact on Revenue	► \$19,000				



Care Gap Closure Study

	DIAGNOSTIC PRO Cardiopulmonary St			Frontera Fax: 877-631-0737 Frontera Phone: 866-945-8700 Client.teamfrontera.com
Patient Name (Last)-PLEASE PRINT				Patient Name (First)-PLEASE PRINT
7 7	1 1		: AM/PM	
Date of Birth	Test Date	Test	Contraction and Contraction Contraction	Ordering Physician
Frontera ID# Gender	Height	Weight	BMI	
All Inclusive ICD If an All inclusive ICD-10 c	CMET/CARDIOPUL -10 Codes cover both Cardiac & odes does not apply, select at le	Pulmonary requi	rements for CMET a	s well as Resting Echo de in the sections below to cover a CMET
CMET only includes all of the following C				
	ALL INCLUS	IVE CODES		
R06.09-Other forms of Dyspnea	R06.02 Short ease provide ALL applicable		or all test(s) order	Other ICD-10 code(s) and narrative:
ARDIAC CODES Please select:			Tester and the	
110 Essential Primary Hypertension* 120.0 Unstable angina* 120.8 Other forms of angina pectoris* 124.0 Acute coronary thrombosis not resulting in my 124.8 Other forms of acute ischemic heart disease* 125.110 Atherosclerotic heart disease of native coronary 125.5 Ischemic cardiomyopathy* 127.0 Primary pulmonary hypertension* 127.89 Other specified pulmonary heart diseases 134.2 Nonrheumatic mitral (valve) stenosis*		ctoris*	135.1 Nonr 142.1 Obst 148.19 Oth 150.22 Chro 150.89 Oth R00.2 Palp R00.8 Abno	ormal Heart Sounds-Other sonal History of COVID-19*
Other ICD-10 code(s) and narrative LMONARY CODES	Please refer to	CMET area abo	ove	*May require additional coding
J47.0 Bronchiectasis w/ acute lower respiratory infed				h-Other Specified
J47.1 Bronchiectasis w/ (acute) exacerbation			R06.01 Ort	
J47.9 Bronchiectasis- uncomplicated				ortness of breath
J84.111 Idiopathic interstitial pneumonia-NOS	Si			er forms of dyspnea
J84.112 Idiopathic pulmonary fibrosis			R06.1 Strid	
J84.113 Idiopathic non-specific interstitial pneumoni J84.114 Acute interstitial pneumonitis	tis		R06.2 Whe	
J84.115 Respiratory bronchiolitis interstitial lung dise	200			dic breathing rventilation
R05.1 Acute Cough	-036			hypnea, NOS
R05.2 Subacute Cough				er abnormalities of breathing
R05.3 Chronic Cough				sonal History of COVID-19*
R05.4 Cough Syncope				onal HX of other diseases of the respiratory system*
Other ICD-10 code(s) and narrative ILMONARY FUNCTION TEST CODES Please select :	Pulmonary Function	Test	Pulmona	<i>May require additional coding</i> ary Function Test Pre/Post Bronchodilator
J22 Acute (lower) respiratory (tract) infection NOS	J45.40 Moderate Persis	stent Asthma-NC	05* 806.0	2 Shortness of Breath
J40 Bronchitis-NOS	J45.50 Severe Persist		100 () () () () () () () () () (Wheezing
J44.0 COPD w/Acute LRI	J45.909 Unspecified /			9 Other Forms of Dyspnea
J44.1 COPD w/Acute Exacerbation	J45.990 Exercise Bron			1 Apnea-NOS*
J43.9 Emphysema-unspecified	J45.991 Cough varian			9 Other abnormalities of breathing
J45.20 Mild Intermittent Asthma-NOS*	J45.998 Other asthma			8 PRSN History of COVID-19*
J45.30 Mild Persistent Asthma-NOS*	R05.8 Other specified	i cough*	Z87.09	PRSN HX of other diseases of the respiratory system
Other ICD-10 code(s) and narrative	- reus a stand la	TOUR OF	l laure et	*May require additional coding
	ting ECHO-Complete Stress 149.2 Premature Be	s ECHO-Complet		HO-Follow-Up/Ltd Study Please specifis:
109.89 Other specified rheumatic heart disease 110 Essential Primary Hypertension*	149.2 Premature Be		the second se	cope & Collapse* N Findings of Lung Field-unspecified*
11.0 Hypertensive heart disease W/ Heart failure*	R00.2 Palpitations		and the second se	indings or Lung Field-unspecified. findings on diagnostic imaging of heart and coronary circulation
11.9 Hypertensive heart disease W/O Heart failure*			and the second sec	ABN EKG*
I25.2 Old myocardial infarction*	R01.1 Cardiac Mur		and a second	Adverse effect of NOS Drug** cannot be billed alone
125.89 Other forms of chronic ischemic heart disease *			U07.1 CC	
134.1 Mitral Valve Prolapse	R06.09 Other Form	ns of Dyspnea	Z86.16 P	RSN HX of COVID-19*
134.2 Nonrheumatic mitral (valve) stenosis	R07.81 Pleurodynia		287.74 PRSN	HX of (corrected) congenital malformations of heart and circulatory system
I35.2 Aortic Stenosis Other ICD-10 code(s) and narrative	R07.82 Chest Pain-	Intercostal*		*May require additional coding
A REAL PROPERTY AND A REAL				

Key Performance Indicators	2022	2023 🔀		
Number of Orders	7.5 order / Mo	72 orders / Mo		
Gaps Identified	Order Volume (By Test) • AAA Scan (6) • Arterial Doppler (31) • Carotid Doppler (16) • Pulmonary Function Test (12) • Resting Echocardiogram (7)			
Gaps Closed	15%	25%		
Risk-Adjusted Factor (RAF) S	Risk-Adjusted Factor (RAF) Score Improvement			
Impact on Revenue	Impact on Revenue per Provider			

Conclusions and Implications

- Promising impact of ML-enabled workflows for primary care
- Eliminating manual search, data sourcing, and data entry saves healthcare providers time & money
- Identifying at-risk patients with a clinical need for diagnostic evaluations and preventative screenings will proactively close care gaps and foster better health outcomes

Integrating AI/ML technology within a provider's workflow can reduce administrative burdens and improve operational efficiency and fiscal accountability.

Challenges and Lessons

EMR Implementation

- Fragmented EMR workflows
- Lack of transparency in EMR for patients being seen by specialists improving transparency will lead to better care gap identification & diagnostic order automation

Care Gap Order Automation

- Patient engagement was the biggest factor that contributed to noncompliance reasons (e.g., cancelled orders, clinical cause, lack of patient response, patient refusal)
 - Improving patient engagement will lead to higher order conversion

Next Steps

ML & AI Explainability

adoption of ML & AI tools in the clinical space

Patient Risk Management

RAF Score

Additional Performance Metrics of Provider Proficiency

• CMS Star Rating, HEDIS Score, MIPS Score, CAHPS

• Focusing on transparency behind ML & AI decisions will foster better

Explainability

Why Digital Health Technologies should care:

- non-technical users don't understand them well (blackbox)
- How or when they work (background)
- Grasping the impact across society

Can easily go wrong with big tech

- Transparency-washing, (Zalnieriute, 2021)
- Gamification, (Charles AE Goodhart. 1984. Problems of monetary management: the uk experience. In Monetary theory and practice, pages 91–121. Springer)
- Promote surveillance, (Han, 2015; Mohamed et al., 2020; Birchall, 2021)

Foundation Model Transparency Index Scores, 2023

Company				
Llama 2	C			
BLOOMZ	0			
GPT-4				
Stable Diffusion 2	e			
PaLM 2	e			
Claude 2				
Command	C			
Jurassic-2	e			
Inflection-1	e			
Titan Text				
	Llama 2 BLOOMZ GPT-4 Stable Diffusion 2 PaLM 2 Claude 2 Command Jurassic-2 Inflection-1			

Source: Foundation Model Transparency Index (stanford.edu)



Poorest Performing Areas

Upstream Indicators

Copyrighted data: For all data used in building the model, is the associated copyright status disclosed?

Data license: For all data used in building the model, is the associated license status disclosed?

Personal information in data: For all data used in building the model, is the inclusion or exclusion of personal information in that data disclosed?

Use of human labor: Are the phases of the data pipeline where human labor is involved disclosed?

Employment of data laborers: Is the organization that directly employs the people involved in data labor disclosed for each phase of the data pipeline?

Geographic distribution of data laborers: Is geographic information regarding the people involved in data labor disclosed for each phase of the data pipeline?

Wages: Are the wages for people who perform data labor disclosed?

Instructions for creating data Are the instructions given to people who perform data labor disclosed?

Labor protections: Are the labor protections for people who perform data labor disclosed?

Third party partners: Are the third parties who were or are involved in the development of the model disclosed?

Downstream Indicators

Permitted and prohibited users: Is a description of who can and cannot use the model disclosed?

Permitted, restricted, and prohibited uses: Are permitted, restricted, and prohibited uses of the model disclosed?

Usage policy enforcement: s the enforcement protocol for the usage policy disclosed?

Justification for enforcement action: Do users receive a justification when they are subject to an enforcement action for violating the usage policy?

Usage policy violation appeals mechanism: Is a mechanism for appealing potential usage policy violations disclosed?

Permitted, restricted, and prohibited model behaviors: Are model behaviors that are permitted, restricted, and prohibited disclosed?

Model behavior policy enforcement: Is the enforcement protocol for the model behavior policy disclosed?

Interoperability of usage and model behavior policies: Is the way that the usage policy and the model behavior policy interoperate disclosed?

Model Indicators

Risks description: Are the model's risks disclosed?

Risks demonstration: Are the model's risks demonstrated?

Unintentional harm evaluation: Are the model's risks related to unintentional harm rigorously evaluated, with the results of these evaluations reported prior to or concurrent with the initial release of the model?

External reproducibility of unintentional harm evaluation: Are the evaluations of the model's risks related to unintentional harm reproducible by external entities?

Intentional harm evaluation: Are the model's risks related to intentional harm rigorously evaluated, with the results of these evaluations reported prior to or concurrent with the initial release of the model?.

External reproducibility of intentional harm evaluation: Are the evaluations of the model's risks related to intentional harm reproducible by external entities?

Third party risks evaluation: Are the model's risks evaluated by third parties?

Mitigations description: Are the model mitigations disclosed?

Mitigations demonstration: Are the model mitigations demonstrated?

Mitigations evaluation: Are the model mitigations rigorously evaluated, with the results of these evaluations reported?

External reproducibility of mitigations evaluation: Are the model mitigation evaluations reproducible by external entities?

Third party mitigations evaluation: Can the model mitigations be evaluated by third parties?

Trustworthiness evaluation: Is the trustworthiness of the model rigorously evaluated, with the results of these evaluations disclosed?

External reproducibility of trustworthiness evaluation: Are the trustworthiness evaluations reproducible by external entities?

Inference duration evaluation: Is the time required for model inference disclosed for a clearly-specified task on a clearly-specified set of hardware?

Inference compute evaluation: Is the compute usage for model inference disclosed for a clearly-specified task on a clearly-specified set of hardware?

Source: Foundation Model Transparency Index (stanford.edu)



Foundation Model Transparency Index Scores, 2023



Closed Developers struggle in:

Data, Data Labor, Data Access, Compute, Data Mitigation, Model Basics, Inference

Open Developers struggle in:

Model Mitigation, Trustworthiness, Model Behavior Policy

© 2023 ParaDocsHealth

255,







Omar Mohtar (MD/PHD)

Chief Executive Officer Physician Innovator

Dhini Nasution (MD/MAP)

Chief Operating Officer **Clinical AI Specialist**



President / Clinical Champion **Cypress Physicians Association**



Vibhav Jha (MS)

Chief Technology Officer Machine Learning Specialist

LEADERSHIP



Matthew Segar (MD/MS) **Cardiology Fellow Texas Heart Institute**

Built by Doctors, for Doctors





Glenn Davis (MD)

Maria Berdayes (**DO**)

President / Medical Director Millennium Physicians IPA

Lance Black (MD/MBID)

Healthcare Advisor / TMCi Medical Director / 3ive Labs

ESS GANEY





(MD)

Founder / CEO Hamilton Health Box

Kyle Robertson (JD)

Healthcare Entrepreneur NarrativeDx / Press Ganey

ADVISORY BOARD





Remember the Dream

2450 Holcombe Blvd, Houston, TX 77021
www.paradocshealth.com
